Strong Revenue Growth
Total revenue for the fourth quarter was $80.2 million, representing a growth of over 12% year-over-year. MedTech growth was over 20% and med device growth was more than 6%.
Auryon Platform Success
Auryon has delivered its sixteenth consecutive quarter of double-digit increases, with revenue reaching $15.6 million, growing 19.7% compared to last year.
Mechanical Thrombectomy Growth
The mechanical thrombectomy portfolio showed approximately 45% year-over-year growth, with AngioVac and AlphaVac contributing significantly.
Operational Efficiency
Generated positive adjusted EBITDA and over $15 million of free cash flow in the fourth quarter. Expecting $15 million in annualized savings by fiscal 2027.
NanoKnife and Regulatory Milestones
NanoKnife achieved key clinical, reimbursement, and regulatory milestones with a CPT Category I code granted for prostate and liver treatments effective January 1, 2026.